Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 5/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2032898 | 0.78 | MGLL (0.63) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL29366407 | 0.74 | DPP4 (0.78) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL9612014 | 0.74 | DPP4 (0.63) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL2820118 | 0.74 | DPP4 (0.78) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL2481189 | 0.74 | DPP4 (0.80) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL30954668 | 0.73 | ANPEP (0.67) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL29286159 | 0.73 | ANPEP (0.58) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL17531021 | 0.73 | ANPEP (0.67) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL15437793 | 0.72 | DPP4 (0.55) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL21570790 | 0.71 | DPP4 (0.42) | DPP4NR1H2NR1H3ANPEPFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301270-B2 | Compositions and methods for quadricyclane modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170152234-A1 | COMPOSITIONS AND METHODS FOR QUADRICYCLANE MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-01 | — | — | US | disclosed |
| US-20170152234-A1 | COMPOSITIONS AND METHODS FOR QUADRICYCLANE MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-01 | — | — | US | disclosed |
| US-9556195-B2 | Compositions and methods for quadricyclane modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556195-B2 | Compositions and methods for quadricyclane modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-31 | — | — | US | disclosed |
| US-20130244267-A1 | COMPOSITIONS AND METHODS FOR QUADRICYCLANE MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-09-19 | — | — | US | disclosed |
| US-20130244267-A1 | COMPOSITIONS AND METHODS FOR QUADRICYCLANE MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-09-19 | — | — | US | disclosed |
| EP-0545590-B1 | Heat curable organopolysiloxane compositions | GEN ELECTRIC (US) | 1997-02-05 | — | — | EP | disclosed |
| EP-0545590-A1 | Heat curable organopolysiloxane compositions | GENERAL ELECTRIC COMPANY (US) | 1993-06-09 | — | — | EP | disclosed |
| US-5206329-A | Containing silicon hydride, platinum catalyst and triazolinedione polymerization inhibitor | GENERAL ELECTRIC COMPANY (US) | 1993-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152234-A1 | COMPOSITIONS AND METHODS FOR QUADRICYCLANE MODIFICATION OF BIOMOLECULES | MYLK2, TOP2A, PYGM | DPP4 4540/4885NR1H2 3606/4885NR1H3 3507/4885 |
| US-10301270-B2 | Compositions and methods for quadricyclane modification of biomolecules | MYLK2, TOP2A, PYGM | DPP4 4540/4885NR1H2 3606/4885NR1H3 3507/4885 |
| US-20130244267-A1 | COMPOSITIONS AND METHODS FOR QUADRICYCLANE MODIFICATION OF BIOMOLECULES | MYLK2, TOP2A, PYGM | DPP4 4540/4885NR1H2 3606/4885NR1H3 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.